A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

被引：0
|
作者：
Jeremy Holmes
David Dunlop
Lindsay Hemmett
Peter Sharplin
Uday Bose
机构：
[1] PMSI Healthcare,
[2] Glasgow Royal Infirmary,undefined
[3] Aventis Pharma,undefined
[4] PMSI Healthcare,undefined
[5] White Lion House,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Docetaxel; Well Supportive Care; Administration Cost; Nurse Time; Docetaxel Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Whilst lung cancer is the most common form of cancer in England and Wales (annual incidence rate of 50 per 100 000) it does not always receive the policy attention accorded to other types of cancer, such as breast and colorectal. Nevertheless, the burden of lung cancer is significant and the UK NHS Plan for cancer has set out the government’s commitment to improving all cancer services. The question faced by the NHS is which interventions are most cost effective in implementing this plan.
引用
收藏
页码：581 / 589
页数：8
相关论文
共 50 条
  • [21] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [22] Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
    Calpe-Armero, Pablo
    Ferriols-Lisart, Rafael
    Ferriols-Lisart, Francisco
    Perez-Pitarch, Alejandro
    [J]. CHEMOTHERAPY, 2017, 62 (06) : 374 - 380
  • [23] Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Liu, Gordon
    Xie, Feng
    Sheng, Yanan
    Shi, Luwen
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (11) : 2308 - 2320
  • [24] Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
    Laack, E
    Dierlamm, T
    Knuffmann, C
    Popp, J
    Schmied, B
    Dürk, H
    Wacker-Backerhaus, G
    Zeller, W
    Verpoort, K
    Fiedler, W
    Hossfeld, DK
    [J]. LUNG CANCER, 2002, 36 (03) : 303 - 307
  • [25] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [26] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [27] COST COMPARISON OF ERLOTINIB VERSUS GENERIC DOCETAXEL IN SECOND-LINE NON-SMALL CELL LUNG CANCER IN ITALY
    Schwander, B.
    Ravera, S.
    Giuliani, G.
    Nuijten, M.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A214 - A214
  • [28] Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
    Franchi, Matteo
    Pellegrini, Giacomo
    Corrao, Giovanni
    [J]. PHARMACEUTICALS, 2022, 15 (04)
  • [29] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US
    Zhang, Peng
    Xu, Nong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Djalalov, S.
    Graham, D. M.
    Beca, J.
    Hoch, J. S.
    Tsao, M. S.
    Leighl, N.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
12345